Dupixent does not require the intensive monthly monitoring that isotretinoin requires — there are no mandatory iPledge check-ins, lab tests, or pregnancy tests. However, regular follow-up with your dermatology provider is still important to monitor your response, evaluate side effects (particularly eye symptoms), and adjust your treatment plan if needed. At Honeydew, your care team will schedule check-ins periodically — typically every three to six months once you've stabilized on treatment — and are available to respond to concerns or prescription questions at any time through your dashboard. If you experience significant side effects or your eczema changes, same-week check-ins are available.

Dupixent requires special handling and cold-chain storage that standard retail pharmacies are not equipped to manage. Specialty pharmacies are specifically licensed and equipped to store, dispense, and deliver biologic medications that require refrigeration and careful supply chain management. They also provide dedicated patient support services — including injection training, refill reminders, and insurance coordination — that are specific to complex specialty medications. Honeydew works with specialty pharmacy partners to ensure your Dupixent is delivered on time, properly stored, and your refill schedule is maintained without interruption.

Yes. Honeydew providers can evaluate your eczema and prescribe Dupixent entirely online. After completing your medical intake your provider will assess whether Dupixent is appropriate for your severity and treatment history. If prescribed, your care team handles prior authorization with your insurer, enrolls you in the DUPIXENT MyWay savings program if applicable, and coordinates your first fill through a specialty pharmacy. Dupixent is delivered directly to your door through the specialty pharmacy network.

Dupixent has received FDA approvals for a broad range of inflammatory conditions involving the type 2 immune pathway. Beyond atopic dermatitis and prurigo nodularis, approved indications include moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype, chronic spontaneous urticaria (CSU), and bullous pemphigoid. Honeydew is a dermatology-focused platform and primarily prescribes Dupixent for skin conditions. If you have a non-dermatological condition for which Dupixent may be appropriate, discuss this with your provider — they can evaluate whether Honeydew's scope of care is appropriate or recommend you work with the relevant specialist.

Yes. Dupixent is FDA-approved for prurigo nodularis (PN) in adults — a chronic, intensely itchy skin condition characterized by hard, dome-shaped nodules that develop from persistent scratching. Like atopic dermatitis, prurigo nodularis involves type 2 inflammatory signaling driven by IL-4 and IL-13, which is why dupilumab is effective for both conditions. If you have prurigo nodularis and are seeking treatment, speak with a Honeydew provider at your initial consultation. They will evaluate your condition and determine whether Dupixent or another treatment is appropriate for your presentation.

Dupixent does not have the same pregnancy contraindications as isotretinoin (Accutane). Available data on dupilumab use in pregnancy, while limited, have not shown evidence of increased risk of major birth defects or adverse pregnancy outcomes. That said, because clinical data are limited, the decision to use Dupixent during pregnancy or while trying to conceive should be made collaboratively between you and your provider, weighing the risks of uncontrolled moderate-to-severe eczema during pregnancy against the available safety data. If you are pregnant or planning to become pregnant, discuss this with your Honeydew provider so they can help you make an informed decision for your specific situation.

Yes. Dupixent is FDA-approved for patients with moderate-to-severe atopic dermatitis as young as 6 months of age making it one of the few biologic treatments approved for infants and young children with severe eczema. Dosing for children is based on age and body weight. For children under 18, a parent or guardian must be involved in the initial consultation and ongoing treatment. Clinical trials in pediatric patients have demonstrated safety and efficacy profiles consistent with adult results. If you are seeking Dupixent treatment for your child, please contact our care team at info@honeydewcare.com so we can set up your consultation appropriately.

Dupixent is indicated for adults and children 6 months and older with moderate-to-severe atopic dermatitis whose eczema is not adequately controlled with topical prescription therapies, or for whom topical therapies are not advisable. In practice, good candidates include patients with widespread or severe eczema that isn't controlled with topical steroids or other topical medications, patients who have significant impact on quality of life from itching or flares, and patients who have failed or had inadequate response to prior topical treatments. Most insurance plans require documentation of topical treatment failure as part of prior authorization. Your Honeydew provider will document this history as part of your clinical evaluation.

Yes. Dupixent has one of the most extensively studied long-term safety profiles of any biologic in dermatology. It has been in clinical use since FDA approval in 2017, and long-term extension studies following patients for four or more years have not identified new safety signals or evidence of increasing risk over time. Unlike older immunosuppressants such as cyclosporine or methotrexate, Dupixent does not require routine organ function monitoring and does not carry risks of nephrotoxicity, hepatotoxicity, or significant bone marrow suppression. The most common long-term side effect is the eye-related conjunctivitis described above. Dupixent is intended to be a long-term chronic disease management treatment, and its safety profile supports this use.

Weight gain is not a documented or commonly reported side effect of Dupixent. Unlike oral corticosteroids which are associated with weight gain, fluid retention, and metabolic effects, Dupixent's targeted mechanism does not affect metabolism or appetite. Some patients transitioning from oral steroid-dependent eczema management to Dupixent may notice changes in their body as steroid use decreases, but this is related to reducing steroids rather than a direct effect of dupilumab. If you experience unexpected weight changes while on Dupixent, mention it at your next check-in so your provider can evaluate whether any other factors may be contributing.

The most commonly reported side effects of Dupixent are injection site reactions (redness, swelling, or itching at the injection site) and eye-related issues including conjunctivitis and eye irritation. Injection site reactions are typically mild and tend to decrease over time. Some patients report a temporary worsening of eczema symptoms in the early weeks of treatment as the medication begins working. Less commonly reported side effects include cold sore reactivation (oral herpes), joint pain (arthralgia), and sleep disturbances. Dupixent does not carry the broad immunosuppression risks associated with oral corticosteroids or older systemic eczema treatments — it is a targeted medication with a favorable long-term safety profile that has been studied in clinical trials involving thousands of patients over multiple years.

Yes, eye-related side effects are the most distinctive and commonly reported side effects of Dupixent. Conjunctivitis (pink eye, including allergic and non-infectious types), blepharitis (eyelid inflammation), and dry eye are reported in a meaningful percentage of patients, particularly those with severe atopic dermatitis or a history of eye-related atopic disease. The exact mechanism is not fully understood, but it appears related to IL-4 and IL-13 signaling in the eye. Symptoms include redness, itching, discharge, and irritation. Most cases are mild to moderate and manageable with topical eye drops. Your Honeydew provider will monitor for eye symptoms at check-ins and can recommend an ophthalmology referral if symptoms are persistent or severe.

Because Dupixent manages atopic dermatitis rather than curing it, stopping treatment typically leads to a return of eczema symptoms within weeks to a few months. The speed and severity of symptom return varies by individual. Some patients may find their eczema returns at a lower level of severity than before starting Dupixent, particularly if their skin barrier has had time to recover during treatment. If you are considering stopping or pausing Dupixent for any reason (cost, pregnancy planning, surgery, or otherwise) discuss it with your Honeydew provider before doing so. There may be options to maintain coverage, adjust dosing, or plan a structured pause.

Dupixent is designed for long-term use and manages atopic dermatitis continuously rather than curing it. With sustained treatment, clinical data show approximately 75% of patients achieve significant skin clearance and approximately 70% report meaningful reduction in itching. Long-term real-world studies of patients on Dupixent for two or more years consistently show maintained or improved results over time, with no evidence of diminishing effectiveness. Because Dupixent targets the underlying immune driver of eczema rather than masking surface symptoms, many patients experience progressive improvement the longer they are on treatment. Stopping Dupixent typically leads to a return of symptoms within weeks to months.

Many patients experience a reduction in itching within the first two weeks of starting Dupixent. Itch relief is often the first and most noticeable early sign that the medication is working. Visible skin improvement — reduced redness, less inflammation, and improved skin texture — typically develops more gradually, with meaningful improvement visible in most patients by 16 weeks. Clinical trial data show that approximately 75% of patients see significant improvement in eczema severity by week 16. Some patients with very severe baseline disease see progressive improvement over six months or more as the inflammatory cycle is gradually interrupted. Your Honeydew provider will set realistic expectations at your first visit and track your progress with photo check-ins throughout treatment.

Yes. Dupixent must be stored in the refrigerator at 36F to 46F (2C to 8C). It can be kept at room temperature (up to 77F / 25C) for up to 14 days if needed (for example, when traveling) but should not be returned to the refrigerator after it has warmed to room temperature. Do not freeze Dupixent. Keep it away from direct light and heat. Dupixent is dispensed through specialty pharmacies that understand its storage and handling requirements, and your medication will arrive properly packaged for cold chain delivery. If you have concerns about storage or travel, raise them with your Honeydew care team.

For adults with atopic dermatitis, Dupixent starts with a loading dose, typically two 300mg injections given at the same time on day one, followed by one 300mg injection every two weeks as maintenance. For children and adolescents, dosing is based on body weight, with some patients using 200mg injections on a different schedule.

The loading dose is designed to reach therapeutic drug levels faster, which is why two injections are given upfront rather than one. After the loading dose, most patients receive their maintenance injections every two weeks consistently, though some patients may transition to a monthly schedule in certain clinical contexts. Your Honeydew provider will specify your exact dosing schedule at your first visit.

Dupixent is given as a subcutaneous injection — an injection into the fatty tissue just under the skin, typically in the abdomen, thigh, or upper arm. It comes as a pre-filled syringe or a pre-filled autoinjector pen, and most patients administer it themselves at home. The autoinjector pen is designed for ease of use and does not require you to handle a traditional syringe if that's a concern. Most patients find the process straightforward after the first injection. Your Honeydew provider will walk you through the injection technique at your initial consultation, and the DUPIXENT MyWay program also provides injection training support through specialty pharmacies.

If Dupixent is not accessible due to cost, prior authorization denial, or clinical factors, Honeydew providers can prescribe several alternative systemic therapies for moderate-to-severe atopic dermatitis. These include Adbry (tralokinumab), Ebglyss (lebrikizumab), and Rinvoq (upadacitinib) — all of which are FDA-approved for moderate-to-severe eczema.

If your Dupixent prior authorization is denied, your Honeydew care team can also support an appeal or request a peer-to-peer review with your insurer. Exploring the DUPIXENT MyWay Patient Assistance Program is another option if cost is the barrier. Your provider will work with you to find the most accessible effective treatment for your specific situation.

Ebglyss (lebrikizumab) is a newer biologic approved for moderate-to-severe atopic dermatitis in patients 12 years and older that also selectively targets IL-13 — the same pathway as Adbry, though with a slightly different binding mechanism.

Like Adbry, Ebglyss may offer a less frequent maintenance dosing schedule than Dupixent for patients who respond well. Indirect comparison studies suggest lebrikizumab may offer comparable long-term efficacy to dupilumab for some patients. Because Ebglyss was approved more recently than Dupixent, it has a shorter real-world track record.

Honeydew offers Ebglyss alongside Dupixent, and your provider can help you evaluate which biologic best fits your clinical situation and coverage.

Both Dupixent (dupilumab) and Adbry (tralokinumab) are injectable biologics approved for moderate-to-severe atopic dermatitis in patients 12 years and older. The key mechanistic difference is that Dupixent blocks both IL-4 and IL-13, while Adbry targets IL-13 only. In practice, both produce meaningful eczema clearance. One practical advantage of Adbry is dosing schedule flexibility — patients who respond well may be able to reduce injections to once every four weeks rather than Dupixent's typical every-two-weeks maintenance schedule, which some patients prefer for convenience. Your Honeydew provider will discuss both options and help determine which biologic is the most appropriate fit for your case, including insurance coverage considerations. Honeydew offers both treatments.

Dupixent and Rinvoq are both effective treatments for moderate-to-severe atopic dermatitis but work differently and carry different risk profiles. Dupixent is an injectable biologic given every two weeks that selectively blocks IL-4 and IL-13. Rinvoq is an oral once-daily JAK-1 inhibitor that blocks a broader set of inflammatory signals. Head-to-head clinical data have shown that upadacitinib 30mg may achieve higher rates of skin clearance compared to dupilumab in some patients. However, Rinvoq carries an FDA boxed warning for serious infections, blood clots, major cardiovascular events, and malignancy, risks that Dupixent does not share. For patients who strongly prefer an oral medication or haven't responded adequately to Dupixent, Rinvoq may be considered. For patients who prioritize a favorable long-term safety profile, Dupixent is typically the preferred biologic. Your Honeydew provider will evaluate the right option based on your severity, health history, and treatment goals. Honeydew offers both treatments.

No. As of 2026, there is no FDA-approved generic or biosimilar version of Dupixent (dupilumab). Dupixent is a biologic, a complex molecule derived from living cells, and biosimilars for biologics have a more involved regulatory pathway than generics for small-molecule drugs. No Dupixent biosimilar has been approved for use in the U.S. to date. This means the list price remains high and the savings programs described above, particularly the DUPIXENT MyWay copay card and Patient Assistance Program, are the primary levers for making treatment affordable.

Topical eczema treatments, including corticosteroids, calcineurin inhibitors like tacrolimus, and newer non-steroidal options like ZORYVE (roflumilast), work at the skin surface to reduce local inflammation and symptoms. They are effective for mild-to-moderate eczema but often provide insufficient control for patients with widespread, severe, or chronically recurring disease.

Dupixent works systemically — it's injected and travels through the bloodstream to block the inflammatory signals driving eczema throughout the body. For patients whose eczema hasn't responded adequately to topicals, or whose disease is too widespread or severe for topicals to manage, Dupixent addresses the underlying immune dysfunction rather than just managing surface symptoms. Many patients use Dupixent alongside topicals for comprehensive management.

Yes. Dupixent (dupilumab) is a biologic medication, specifically a monoclonal antibody, designed to target a precise part of the immune system rather than broadly suppressing it. It works by blocking two signaling proteins: interleukin-4 (IL-4) and interleukin-13 (IL-13), both of which play key roles in driving the type 2 inflammatory response underlying atopic dermatitis. By interrupting these specific signals, Dupixent reduces the immune overactivity that causes itching, redness, skin thickening, and barrier dysfunction in eczema without the broad immunosuppression associated with older systemic treatments like oral corticosteroids. This targeted mechanism is why Dupixent has a favorable long-term safety profile compared to non-specific immunosuppressants.

Navigating Dupixent access is often the hardest part of getting started — and it's one of the most important things Honeydew handles for you. Your care team manages prior authorization from end to end, coordinates your enrollment in the DUPIXENT MyWay savings program if applicable, works with specialty pharmacies to ensure delivery timing, and monitors your refill schedule so your supply is never interrupted. If your insurer requires step therapy — meaning you must document failure of other treatments first — your provider will build that documentation as part of your treatment history. The goal is for cost and logistics to be Honeydew's problem, not yours.

Yes to both. Dupixent is covered by the vast majority of insurance plans — approximately 99% of Medicare Part D plans, nearly all ACA marketplace plans, and most commercial and Medicaid plans. However, prior authorization is required for almost all plan types. Insurers typically require documentation that Dupixent is medically appropriate — including evidence of a confirmed moderate-to-severe atopic dermatitis diagnosis and documented failure of topical prescription therapies. Honeydew manages the prior authorization process on your behalf: gathering clinical documentation, submitting to your insurer, and following up on approval. If your initial authorization is denied, your provider can support an appeal with additional documentation.

The DUPIXENT MyWay Patient Assistance Program is a separate savings option for patients who do not qualify for the copay card including those without commercial insurance, those on Medicare or Medicaid, or those experiencing difficulty paying for treatment. Eligibility is evaluated on a case-by-case basis based on household income and other criteria. If you have Medicare Part D, you may also benefit from the $2,100 annual out-of-pocket cap introduced in 2026, after which your plan covers 100% of covered drug costs for the rest of the year. Your Honeydew care team can help you identify the most appropriate program for your coverage situation and connect you with the right resources.

Yes. The DUPIXENT MyWay copay card is the manufacturer's savings program for patients with commercial health insurance including marketplace exchange plans, federal employee plans, and state employee plans. Eligible patients may pay as little as $0 per fill, with an annual maximum benefit of $13,000. The program covers both the 300mg and 200mg formulations.

To enroll, you can apply online through the DUPIXENT MyWay website or call 1-844-DUPIXENT (1-844-387-4936).

Note: the copay card cannot be used with Medicare or Medicaid — patients in those programs may be eligible for the DUPIXENT MyWay Patient Assistance Program instead. Honeydew's care team will help identify and enroll you in the right program at the start of your treatment.

Dupixent's list price is approximately $3,993 to $4,000+ per carton (two injections, a one-month supply) as of early 2026, making it one of the more expensive specialty medications available. However, most patients do not pay the list price. Insurance covers Dupixent for the majority of commercially insured, Medicare, and Medicaid enrollees, though prior authorization is required in most cases. The DUPIXENT MyWay copay card program allows eligible commercially insured patients to pay as little as $0 per fill, with an annual maximum benefit of $13,000. Honeydew's care team handles prior authorization and can connect you with the DUPIXENT MyWay program as part of your treatment setup so that cost and access hurdles are addressed before you fill your first prescription.